Magnusson, Mats O.
Samtani, Mahesh N.
Plan, Elodie L.
Jonsson, E. Niclas
Rossenu, Stefaan
Vermeulen, An
Russu, Alberto
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia
https://doi.org/10.1007/s40262-016-0459-3
Documents that mention this clinical trial
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia
https://doi.org/10.1007/s40262-016-0459-3
Documents that mention this clinical trial
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis
https://doi.org/10.1007/s40261-018-0647-z
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia
https://doi.org/10.1007/s40262-016-0459-3
Article History
First Online: 14 October 2016
Compliance with Ethical Standards
:
: M. O. Magnusson, E. L. Plan and E. N. Jonsson are employees of Pharmetheus and received consultancy fees from Janssen Research & Development. M. N. Samtani, S. Rossenu, A. Vermeulen, and A. Russu are employees of Janssen Research & Development and own Johnson & Johnson stocks and/or stock options.